Population pharmacokinetics of busulfan in children: Increased evidence for body surface area and allometric body weight dosing of busulfan in children

Clinical Cancer Research

Volumn 17, Issue 21, 2011, Pages 6867-6877

  Trame, Mirjam N ^a,b   Bergstrand, Martin ^c   Karlsson, Mats O ^c   Boos, Joachim ^b   Hempel, Georg ^a,b  

^a UNIVERSITY OF MÜNSTER   (Germany)

^b UNIVERSITY HOSPITAL MÜNSTER   (Germany)

^c UPPSALA UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

BUSULFAN; CLONAZEPAM; CYCLOPHOSPHAMIDE; ETOPOSIDE; FLUDARABINE; MELPHALAN; PHENOBARBITAL; THIOTEPA;

ADOLESCENT; ALLOMETRY; AREA UNDER THE CURVE; ARTICLE; BODY SURFACE; BODY WEIGHT; CHILD; COMPARTMENT MODEL; CONTROLLED STUDY; DOSE CALCULATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE REGIMEN; DRUG MEGADOSE; HUMAN; INFANT; LOADING DRUG DOSE; MAJOR CLINICAL STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEIZURE;

ADOLESCENT; ANTINEOPLASTIC AGENTS, ALKYLATING; BODY SURFACE AREA; BODY WEIGHT; BONE MARROW TRANSPLANTATION; BUSULFAN; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; INFANT; INFUSIONS, INTRAVENOUS; INJECTIONS, INTRAVENOUS; MALE; NEOPLASMS; RETROSPECTIVE STUDIES;

EID: 80455173405     PISSN: 10780432     EISSN: 15573265     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-11-0074     Document Type: Article

References (50)

1. Santos GW, Tutschka PJ, Brookmeyer R, Saral R, Beschorner WE, Bias WB, et al. Marrow transplantation for acute nonlymphocytic leukemia after treatment with busulfan and cyclophosphamide. N Engl J Med 1983;309:1347-53. (Pubitemid 14246556)
2. Dix SP, Wingard JR, Mullins RE, Jerkunica I, Davidson TG, Gilmore CE, et al. Association of busulfan area under the curve with venoocclusive disease following BMT. Bone Marrow Transplant 1996;17:225-30. (Pubitemid 26057312)
3. Grochow LB, Jones RJ, Brundrett RB, Braine HG, Chen TL, Saral R, et al. Pharmacokinetics of busulfan: correlation with veno-occlusive disease in patients undergoing bone marrow transplantation. Cancer Chemother Pharmacol 1989;25:55-61. (Pubitemid 20000799)
4. Grochow LB. Busulfan disposition: the role of therapeutic monitoring in bone marrow transplantation induction regimens. Semin Oncol 1993;20:18-25. (Pubitemid 23239401)
5. Slattery JT, Sanders JE, Buckner CD, Schaffer RL, Lambert KW, Langer FP, et al. Graft-rejection and toxicity following bone marrow transplantation in relation to busulfan pharmacokinetics. Bone Marrow Transplant 1995;16:31-42.
6. Vassal G, Koscielny S, Challine D, Valteau-Couanet D, Boland I, Deroussent A, et al. Busulfan disposition and hepatic veno-occlusive disease in children undergoing bone marrow transplantation. Cancer Chemother Pharmacol 1996;37:247-53.
7. Bolinger AM, Zangwill AB, Slattery JT, Glidden D, Desantes K, Heyn L, et al. An evaluation of engraftment, toxicity and busulfan concentration in children receiving bone marrow transplantation for leukemia or genetic disease. Bone Marrow Transplant 2000;25:925-30. (Pubitemid 30255723)
8. McCune JS, Gooley T, Gibbs JP, Sanders JE, Petersdorf EW, Appelbaum FR, et al. Busulfan concentration and graft rejection in pediatric patients undergoing hematopoietic stem cell transplantation. Bone Marrow Transplant 2002;30:167-73. (Pubitemid 34993856)
9. Slattery JT, Clift RA, Buckner CD, Radich J, Storer B, Bensinger WI, et al. Marrow transplantation for chronic myeloid leukemia: the influence of plasma busulfan levels on the outcome of transplantation. Blood 1997;89:3055-60. (Pubitemid 27172594)
10. Andersson BS, Thall PF, Madden T, Couriel D, Wang X, Tran HT, et al. Busulfan systemic exposure relative to regimen-related toxicity and acute graft-versus-host disease: defining a therapeutic window for i.v. BuCy2 in chronic myelogenous leukemia. Biol Blood Marrow Transplant 2002;8:477-85. (Pubitemid 35174821)
11. Russell JA, Kangarloo SB. Therapeutic drug monitoring of busulfan in transplantation. Curr Pharm Des 2008;14:1936-49.
12. Bartelink IH, Bredius RG, Belitser SV, Suttorp MM, Bierings M, Knibbe CA, et al. Association between busulfan exposure and outcome in children receiving intravenous busulfan before hematologic stem cell transplantation. Biol Blood Marrow Transplant 2009;15:231-41.
13. Nguyen L, Fuller D, Lennon S, Leger F, Puozzo C. I.V. busulfan in pediatrics: a novel dosing to improve safety/efficacy for hematopoietic progenitor cell transplantation recipients. Bone Marrow Transplant 2004;33:979-87. (Pubitemid 38744783)
14. Vassal G, Michel G, Esperou H, Gentet JC, Valteau-Couanet D, Doz F, et al. Prospective validation of a novel IV busulfan fixed dosing for paediatric patients to improve therapeutic AUC targeting without drug monitoring. Cancer Chemother Pharmacol 2008;61:113-23. (Pubitemid 47512633)
15. Leger F, Nguyen L, Puozzo C. Exposure equivalence between IV (0.8 mg/kg) and oral (1 mg/kg) busulfan in adult patients. Eur J Clin Pharmacol 2009;65:903-11.
16. Vassal G, Deroussent A, Challine D, Hartmann O, Koscielny S, Valteau-Couanet D, et al. Is 600 mg/m2 the appropriate dosage of busulfan in children undergoing bone marrow transplantation? Blood 1992;79: 2475-9.
17. Yeager AM, Wagner JE Jr, Graham ML, Jones RJ, Santos GW, Grochow LB. Optimization of busulfan dosage in children undergoing bone marrow transplantation: a pharmacokinetic study of dose escalation. Blood 1992;80:2425-8.
18. Shaw PJ, Scharping CE, Brian RJ, Earl JW. Busulfan pharmacokinetics using a single daily high-dose regimen in children with acute leukemia. Blood 1994;84:2357-62. (Pubitemid 24296400)
19. Schiltmeyer B, Klingebiel T, Schwab M, Murdter TE, Ritter CA, Jenke A, et al. Population pharmacokinetics of oral busulfan in children. Cancer Chemother Pharmacol 2003;52:209-16. (Pubitemid 37204534)
20. Hassan M, Ljungman P, Bolme P, Ringden O, Syruckova Z, Bekassy A, et al. Busulfan bioavailability. Blood 1994;84:2144-50. (Pubitemid 24296370)
21. Gibbs JP, Gooley T, Corneau B, Murray G, Stewart P, Appelbaum FR, et al. The impact of obesity and disease on busulfan oral clearance in adults. Blood 1999;93:4436-40. (Pubitemid 29279287)
22. Vassal G, Fischer A, Challine D, Boland I, Ledheist F, Lemerle S, et al. Busulfan disposition below the age of three: alteration in children with lysosomal storage disease. Blood 1993;82:1030-4. (Pubitemid 23221692)
23. Hassan M, Fasth A, Gerritsen B, Haraldsson A, Syruckova Z, van den BH, et al. Busulphan kinetics and limited sampling model in children with leukemia and inherited disorders. Bone Marrow Transplant 1996;18:843-50. (Pubitemid 26395196)
24. Hassan M, Oberg G, Bekassy AN, Aschan J, Ehrsson H, Ljungman P, et al. Pharmacokinetics of high-dose busulphan in relation to age and chronopharmacology. Cancer Chemother Pharmacol 1991;28:130-4.
25. Buggia I, Zecca M, Alessandrino EP, Locatelli F, Rosti G, Bosi A, et al. Itraconazole can increase systemic exposure to busulfan in patients given bone marrow transplantation. GITMO (Gruppo Italiano Trapianto di Midollo Osseo). Anticancer Res 1996;16:2083-8. (Pubitemid 26270729)
26. Fitzsimmons WE, Ghalie R, Kaizer H. The effect of hepatic enzyme inducers on busulfan neurotoxicity and myelotoxicity. Cancer Chemother Pharmacol 1990;27:226-8.
27. Hassan M, Oberg G, Bjorkholm M, Wallin I, Lindgren M. Influence of prophylactic anticonvulsant therapy on high-dose busulphan kinetics. Cancer Chemother Pharmacol 1993;33:181-6. (Pubitemid 23361064)
28. Gibbs JP, Liacouras CA, Baldassano RN, Slattery JT. Up-regulation of glutathione S-transferase activity in enterocytes of young children. Drug Metab Dispos 1999;27:1466-9.
29. Czerwinski M, Gibbs JP, Slattery JT. Busulfan conjugation by glutathione S-transferases alpha, mu, and pi. Drug Metab Dispos 1996;24:1015-9. (Pubitemid 26314555)
30. Johnson L, Orchard PJ, Baker KS, Brundage R, Cao Q, Wang X, et al. Glutathione S-transferase A1 genetic variants reduce busulfan clearance in children undergoing hematopoietic cell transplantation. J Clin Pharmacol 2008;48:1052-62.
31. Ansari M, Lauzon-Joset JF, Vachon MF, Duval M, Theoret Y, Champagne MA, et al. Influence of GST gene polymorphisms on busulfan pharmacokinetics in children. Bone Marrow Transplant 2010;45:261-7.
32. Zwaveling J, Press RR, Bredius RG, van Derstraaten TR, den HJ, Bartelink IH, et al. Glutathione S-transferase polymorphisms are not associated with population pharmacokinetic parameters of busulfan in pediatric patients. Ther Drug Monit 2008;30:504-10.
33. Eberly AL, Anderson GD, Bubalo JS, McCune JS. Optimal prevention of seizures induced by high-dose busulfan. Pharmacotherapy 2008;28:1502-10.
34. Nguyen L, Leger F, Lennon S, Puozzo C. Intravenous busulfan in adults prior to haematopoietic stem cell transplantation: a population pharmacokinetic study. Cancer Chemother Pharmacol 2006;57:191-8. (Pubitemid 41779838)
35. Oechtering D, Schiltmeyer B, Hempel G, Schwab M, Wurthwein G, Murdter T, et al. Toxicity and pharmacokinetics of i.v. busulfan in children before stem cell transplantation. Anticancer Drugs 2005;16:337-44. (Pubitemid 40283950)
36. Bartelink IH, Bredius RG, Ververs TT, Raphael MF, van KC, Bierings M, et al. Once-daily intravenous busulfan with therapeutic drug monitoring compared to conventional oral busulfan improves survival and engraftment in children undergoing allogeneic stem cell transplantation. Biol Blood Marrow Transplant 2008;14:88-98. (Pubitemid 350286741)
37. Blanz J, Rosenfeld C, Proksch B, Ehninger G, Zeller KP. Quantitation of busulfan in plasma by high-performance liquid chromatography using postcolumn photolysis. J Chromatogr 1990;532:429-37. (Pubitemid 20372568)
38. Murdter TE, Coller J, Claviez A, Schonberger F, Hofmann U, Dreger P, et al. Sensitive and rapid quantification of busulfan in small plasma volumes by liquid chromatography-electrospray mass spectrometry. Clin Chem 2001;47:1437-42. (Pubitemid 32678823)
39. Beal SL, Sheiner BL, Boeckmann A. NONMEM user's guides. San Francisco, CA: University of California; 1999.
40. Ette EI, Ludden TM. Population pharmacokinetic modeling: the importance of informative graphics. Pharm Res 1995;12:1845-55. (Pubitemid 26031769)
41. Mandema JW, Verotta D, Sheiner LB. Building population pharmacokinetic- pharmacodynamic models. I. Models for covariate effects. J Pharmacokinet Biopharm 1992;20:511-28. (Pubitemid 23034413)
42. Anderson BJ, McKee AD, Holford NH. Size, myths and the clinical pharmacokinetics of analgesia in paediatric patients. Clin Pharmacokinet 1997;33:313-27. (Pubitemid 27480936)
43. Bergstrand M, Hooker AC, Wallin JE, Karlsson MO. Prediction-corrected visual predictive checks for diagnosing nonlinear mixed-effects models. AAPS J 2011;13:143-51.
44. Lindbom L, Pihlgren P, Jonsson EN. PsN-Toolkit-A collection of computer intensive statistical methods for non-linear mixed effectmodeling usingNONMEM.ComputMethods ProgramsBiomed 2005;79:241-57. (Pubitemid 41196689)
45. Jonsson EN, Karlsson MO. Xpose-an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed 1999;58:51-64. (Pubitemid 29049052)
46. HolfordNH. A size standard for pharmacokinetics. Clin Pharmacokinet 1996;30:329-32. (Pubitemid 26177179)
47. Anderson BJ, Holford NH. Mechanism-based concepts of size and maturity in pharmacokinetics. Annu Rev Pharmacol Toxicol 2008;48:303-32. (Pubitemid 351738156)
48. Michel G, Valteau-Couanet D, Gentet JC, Esperou H, Socie G, Mechinaud F, et al. Weight-based strategy of dose administration in children using intravenous busulfan: clinical and pharmacokinetic results. Pediatr Blood Cancer 2011 Jan 19. [Epub ahead of print].
49. Hansson EK, Wallin JE, Lindman H, Sandstrom M, Karlsson MO, Friberg LE. Limited inter-occasion variability in relation to inter-individual variability in chemotherapy-induced myelosuppression. Cancer Chemother Pharmacol 2010;65:839-48.
50. Bleyzac N. The use of pharmacokinetic models in paediatric oncohaematology: effects on clinical outcome through the examples of busulfan and cyclosporine. Fundam Clin Pharmacol 2008;22:605-8.